Chicago Partners Investment Group LLC Lowers Position in Eli Lilly and Company (NYSE:LLY)

Chicago Partners Investment Group LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 7.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,431 shares of the company’s stock after selling 1,502 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Eli Lilly and Company were worth $12,314,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Norges Bank acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $5,992,890,000. International Assets Investment Management LLC raised its position in Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Sapient Capital LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $682,139,000. Vanguard Group Inc. raised its position in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Finally, Comerica Bank acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $345,781,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded down $4.88 during trading on Friday, reaching $878.45. The company had a trading volume of 2,023,264 shares, compared to its average volume of 2,475,545. The firm has a market capitalization of $834.89 billion, a price-to-earnings ratio of 129.37, a price-to-earnings-growth ratio of 1.93 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock’s fifty day moving average price is $785.96 and its 200 day moving average price is $717.55. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $885.06.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the prior year, the company posted $1.62 earnings per share. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. As a group, equities research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 75,510 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $860.78, for a total value of $64,997,497.80. Following the sale, the insider now owns 97,793,810 shares of the company’s stock, valued at $84,178,955,771.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 75,510 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $860.78, for a total value of $64,997,497.80. Following the completion of the sale, the insider now owns 97,793,810 shares in the company, valued at $84,178,955,771.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 552,804 shares of company stock valued at $462,119,714. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Tuesday. The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Citigroup boosted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $787.53.

Get Our Latest Stock Report on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.